Hwang S, Kwan K C
J Pharm Sci. 1980 Jan;69(1):77-80. doi: 10.1002/jps.2600690121.
Assumptions attendant to model-independent bioavailability estimation were reexamined. Particular attention was given to the situation where an intravenous reference is not available and nonrenal clearance is assumed to be constant between treatments. Under these circumstances, the previously proposed approximation was compared with other bioavailability estimators. On the basis of error analysis, a procedure was devised to yield optimal relative bioavailability estimates.
重新审视了与模型无关的生物利用度估计相关的假设。特别关注了无法获得静脉注射参比制剂且假定各治疗之间非肾清除率恒定的情况。在这些情况下，将先前提出的近似方法与其他生物利用度估计方法进行了比较。基于误差分析，设计了一种程序以得出最佳相对生物利用度估计值。
